Evidence map›GLP-1 receptor agonists × all-cause mortality›PMID 40637782›Full record

SynthesisClinical research in cardiology : official journal of the German Cardiac Society2026

Impact of GLP-1 receptor agonists on cardiovascular outcomes in heart failure with preserved ejection fraction (HFpEF): systematic review and meta-analysis.

Antony Gonzales-Uribe, Renato Ruiz-Cortez, Nicole Collantes-Silva, Lorenzo Olivero, Raksheeth Agarwal, Sebastian Arambulo-Castillo, Alonso Garcia-Geng, Xiajie Lyu, Daniel Mendoza-Quispe, Victor Becerra-Gonzales and 1 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Clinical research in cardiology : official journal of the German Cardiac Society, 2026. The graph read 1 number from its abstract, feeding 1 cell of the map: it supports the treatment in 1. Cited by 6 papers, 2 of them syntheses that pooled it.

1number the graph read from it
1cell of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

← favours the treatmentfavours the comparator →
1 · no effect
Composite of all-cause mortality and HF hospitalizationGLP-1 RAs vs placebo or other hypoglycemic agentsfavours the treatment · heart_failure, ascvdfeeds one cell of the map
HR 0.730.60 to 0.90
GLP-1 RAs reduced the composite outcome of all-cause mortality and HF hospitalization by 27% (HR 0.73; 95% CI: 0.60-0.90; I CONCLUSION: GLP-1 RAs may significantly lower the combined risk of mortality and hospitalization in patients with HFpEF.
FeedsGLP-1 receptor agonists×all-cause mortality

clause the extractor read what became the number

2 · Its place on the map

Where it lands on the map

Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.

supports the treatmentfavours the comparatorno clear differenceread, but no usable result
3 · What it changes

What it adds to each cell

For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.

GLP-1 receptor agonists×all-cause mortality

SupportsOpen on the map →What to test next →

11 readable studies in this cell: 7 favour the treatment, 4 find no difference, 0 favour the comparator.

Belief with this paper
0.87replicated · 7 families support, 1 contradict · against placebo
Without itNot a counted family in this claim, so removing it changes nothing.
← favours the treatmentfavours the comparator →
1 · no effect
NCT0399313226,774 enrolled · 2018
HR 0.990.83 to 1.18
NCT0357459717,604 enrolled · 2018
HR 0.800.72 to 0.89
NCT013949529,901 enrolled · 2011
HR 0.880.79 to 0.99
NCT039143269,651 enrolled · 2019
HR 0.860.77 to 0.96
NCT011790489,341 enrolled · 2010
HR 0.870.78 to 0.97
NCT038191533,533 enrolled · 2019
HR 0.760.66 to 0.88
NCT017204463,297 enrolled · 2013
HR 0.740.58 to 0.95
NCT026927163,183 enrolled · 2017
HR 0.790.57 to 1.11
Effects of Liraglutide on Clinical Stability Among Patients With Advan…PMID 27483064 · 300 enrolled · 2013
HR 1.100.57 to 2.14
[SURPASS CVOT : cardiovascular benefits with tirzepatide versus dulagl…PMID 41815032 · 2026
HR 0.840.75 to 0.94
Risk of adverse events with liraglutide in heart failure with reduced …PMID 36082522 · 2023
IRR 1.760.92 to 3.37

This paper's own estimate is on a different scale from the rest of the cell, so it is not drawn here.

4 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

5 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
6 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

7 · Who and what money

Authors and funding

11 authors.

Antony Gonzales-UribeJacobi Medical Center/Albert Einstein College of Medicine, 1400 Pelham Parkway South, Bronx, NY, 10461, USA. antonyuri139613@gmail.com.ORCID http://orcid.org/0000-0001-5068-9596
Renato Ruiz-CortezFacultad de Medicina Alberto Hurtado, Universidad Peruana Cayetano Heredia, Lima, Peru.
Nicole Collantes-SilvaDepartment of Internal Medicine, University of New Mexico, Albuquerque, NM, 87131, USA.
Lorenzo OliveroJacobi Medical Center/Albert Einstein College of Medicine, 1400 Pelham Parkway South, Bronx, NY, 10461, USA.
Raksheeth AgarwalJacobi Medical Center/Albert Einstein College of Medicine, 1400 Pelham Parkway South, Bronx, NY, 10461, USA.
Sebastian Arambulo-CastilloDivision of General Internal Medicine, Department of Medicine, Albert Einstein School of Medicine, Montefiore Medical Center, Wakefield Campus, Bronx, NY, USA.
Alonso Garcia-GengUniversity of Applied Science, Lima, Peru.
Xiajie LyuJacobi Medical Center/Albert Einstein College of Medicine, 1400 Pelham Parkway South, Bronx, NY, 10461, USA.
Daniel Mendoza-QuispeSt. Barnabas Hospital, CUNY School of Medicine, The City University of New York, New York, NY, USA.
Victor Becerra-GonzalesAdvanced Cardiac Imaging, NYU Langone Health-Grossman Long Island School of Medicine, Mineola, NY, USA.
Hoda ButrousDivision of Cardiology, University of Miami Miller School of Medicine, Miami, FL, USA.

Funding

No grant is acknowledged in the PubMed record.

8 · The paper itself

Abstract

The marked sentences are the ones the graph read a number from.

backgroundPharmacologic therapies for heart failure with preserved ejection fraction (HFpEF) have shown limited efficacy, and the impact of GLP-1 receptor agonists (GLP-1 RAs) remains unclear. This meta-analysis evaluates their effects on mortality and hospitalization in HFpEF.

methodsWe obtained the data from PubMed, Scopus, Embase, and Web of Science for all eligible studies, including clinical trials (RCT) and cohorts comparing GLP-1 RAs to placebo or other hypoglycemic agents in patients with HFpEF published until December 31st, 2024. The Grade and Risk of Bias (ROB) tool assessment was used to evaluate the quality of the evidence. Data on the primary outcome, the composite of all-cause mortality and HF-related hospitalization, was pooled using a random effect meta-analysis with additional subgroup analyses. Risk ratios (RR), hazard ratios (HR), or mean differences with 95% confidence intervals (CI) are presented accordingly.

resultsSix studies (five RCTs, one cohort) including 4043 patients were analyzed. Five studies evaluated semaglutide and one tirzepatide. GLP-1 RAs reduced the composite outcome of all-cause mortality and HF hospitalization by 27% (HR 0.73; 95% CI: 0.60-0.90; I

conclusionGLP-1 RAs may significantly lower the combined risk of mortality and hospitalization in patients with HFpEF.

Indexed as

Glucagon-Like Peptide-1 Receptor AgonistsHeart FailureHypoglycemic AgentsStroke VolumeHospitalizationHumansSemaglutideTirzepatideGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsSemaglutideTirzepatideGLP-1 receptor antagonistHeart failure with preserved ejection fractionHospitalizationMeta-analysisMortalitySemaglutideTirzepatide

Identifiers

PMID40637782

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.